Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

NCT04508725 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT04508725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Lead sponsor
Stanford University
Phase
Not applicable
Overall status
Completed
Start date
December 5, 2020
Completion date
November 30, 2023
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer, metastatic renal cell carcinoma, renal cell carcinoma